Clinical trials: Liver Biopsy
Alcohol Use Disorder
Hepatic Lipid Metabolism-Alcohol Use Disorder
Patients with hepatic steatosis due to alcohol will be offered liver biopsies when they enter a detoxification program. The first biopsy will occur in the first week of admission and the second in the fourth week when the…
- Trial name
- NCT07191561
- Testing
- Liver biopsy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NASH - Nonalcoholic Steatohepatitis
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
- Trial name
- ENLIVEN (NCT04929483)
- Testing
- BIO89-100
- Where
- 89 sites in United States, Puerto Rico
- Volunteers
- 222 people
- Sponsor
- 89bio, Inc.
Liver Fibrosis Due to NASH
Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate whether SIM (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the clinical progression to cirrhosis in participants…
- Trial name
- NCT01672866
- Testing
- SIM
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 222 people
- Sponsor
- Gilead Sciences
Liver Cirrhosis
Transient Elastography in Autoimmune Hepatitis
Recent, research has focused on the evaluation of non-invasive methods for the assessment of liver fibrosis in patients with chronic liver disease. Among these methods, transient elastography is the most promising.
- Trial name
- NCT01905254
- Testing
- Transient elastography (TE), Liver biopsy
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
NASH - Nonalcoholic Steatohepatitis, Liver Fibroses
Liquid Biopsy for NASH and Liver Fibrosis
Nonalcoholic fatty liver disease (NAFLD) has evolved to represent the most common cause of chronic liver disease globally. Today, NAFLD is a leading indication for liver transplantation and a major etiology for hepatocellular…
- Trial name
- LIBRA (NCT04677101)
- Testing
- Liver Biopsy
- Where
- 2 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Catholic University of the Sacred Heart
Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency
Hepatic Histopathology in Urea Cycle Disorders
This is a multi-site, retrospective chart review as well as a prospective study to evaluate histopathologic findings in liver samples from individuals with any UCD diagnosis.
- Conditions
- Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency, Citrullinemia 1, ARGI Deficiency
- Trial name
- NCT04908319
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Baylor College of Medicine
Liver Fibrosis
Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis
Chronic liver disease is a major health problem worldwide. Liver fibrosis is a key feature in most chronic liver diseases. When identified early, liver fibrosis may be reversible.
- Trial name
- NCT04429100
- Testing
- Magnetic Resonance Imaging
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Chronic Liver Disease, Steatohepatitis
Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy
The purpose of this study is to evaluate non-invasive parameters for staging and grading of chronic hepatopathy in comparison to liver biopsy.
- Conditions
- Chronic Liver Disease, Steatohepatitis, Fibrosis
- Trial name
- NCT01246388
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Tischendorf, Jens, M.D.
Primary Sclerosing Cholangitis (PSC)
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
The purpose of this study is to evaluate whether simtuzumab (GS-6624) is effective at preventing the progression of liver fibrosis in adults with primary sclerosing cholangitis (PSC).
- Trial name
- NCT01672853
- Testing
- Simtuzumab
- Where
- 75 sites in United States, Belgium and 8 more
- Volunteers
- 235 people
- Sponsor
- Gilead Sciences
Fatty Liver, Hepatitis
MRI to Measure Liver Fat Content
This study will determine whether a magnetic resonance imaging (MRI) test of the liver can accurately measure the amount of fat in the liver compared to the results of a liver biopsy.
- Trial name
- NCT00594412
- Testing
- Diagnostic Radiology: 1H-MRS of the liver
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis, Viral, Human
Evaluation and Medico-Economic Study of FIBROSCAN in Patients With Viral Hepatitis
A new approach to the evaluation of liver fibrosis has been proposed using PULSOMETRY. The objective is to evaluate the diagnostic performances of the FIBROSCAN technique, together with non-invasive techniques, and to determine…
- Trial name
- FIBROSTIC (NCT00318682)
- Testing
- FIBROSCAN
- Where
- 2 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, Liver Transplant; Complications
Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation
The use of devices for liver grafts perfusion before transplantation, either hypothermic (HOPE) or normothermic (NMP), is rapidly spreading thanks to the promising results obtained so far in terms of graft survival and…
- Trial name
- NCT06236568
- Testing
- D-HOPE machine perfusion, Liver transplantation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Non-alcoholic Fatty Liver Disease
Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal
Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and…
- Trial name
- NCT06707129
- Testing
- life-style
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Non Alcoholic Steatohepatitis (NASH)
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis…
- Trial name
- NCT04880187
- Testing
- AXA1125
- Where
- 75 sites in United States, Australia and 5 more
- Volunteers
- 273 people
- Sponsor
- Axcella Health, Inc
Hepatocellular Carcinoma (HCC)
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment…
- Trial name
- NCT07303712
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Palo Alto Veterans Institute for Research
Renal Function, Liver Transplant
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.
- Trial name
- NCT01598987
- Testing
- Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
- Where
- 32 sites in United States, Australia and 10 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Advanced Solid Tumor
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor, Colon Rectal Cancer
- Trial name
- POPCORN (NCT06028724)
- Where
- Italy
- Volunteers
- 782 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Hemophilia A, Hemophilia B
Liver Biopsy Following Gene Therapy For Hemophilia
This observational study will obtain liver biopsy samples and evaluate the long-term effect of adeno-associated virus (AAV)-mediated gene therapy on the liver tissue in adult patients with hemophilia A or hemophilia B who have…
- Trial name
- NCT05932914
- Testing
- Liver Biopsy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- St. Jude Children's Research Hospital
Chronic Hepatitis C, Chronic Hepatitis B
Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin
Percutaneous liver biopsy (PLB) is the gold standard for grading necroinflammation and staging fibrosis in patients with chronic viral hepatitis.
- Conditions
- Chronic Hepatitis C, Chronic Hepatitis B, Biopsy, Hemodialysis
- Trial name
- NCT00635310
- Testing
- Percutaneous liver biopsy
- Where
- 5 sites in Taiwan
- Volunteers
- 3,520 people
- Sponsor
- National Taiwan University Hospital
Liver Fibrosis, Liver Inflammation
Ultrasound Based Acoustic Radiation Force Impulse Imaging
ARFI (Ultrasound-based Acoustic Radiation Force Impulse) will be used during ultrasound guided needle biopsy of the liver of children.
- Trial name
- NCT01781208
- Testing
- Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Michigan